Literature DB >> 31965063

Association of the IL16 Asn1147Lys polymorphism with intravenous immunoglobulin resistance in Kawasaki disease.

Hea-Ji Kim1, Jae-Jung Kim1, Sin Weon Yun2, Jeong Jin Yu3, Kyung Lim Yoon4, Kyung-Yil Lee5, Hong-Ryang Kil6, Gi Beom Kim7, Myung-Ki Han8, Min Seob Song9, Hyoung Doo Lee10, Kee Soo Ha11, Young Mi Hong12, Gi Young Jang11, Jong-Keuk Lee13.   

Abstract

Kawasaki disease (KD) is an acute, self-limited vasculitis, mainly affecting children younger than 5 years old, with accompanying fever and signs of mucocutaneous inflammation. Intravenous immunoglobulin (IVIG) is the standard treatment for KD; however, ~15% of patients are resistant to IVIG treatment. To identify protein coding genetic variants influencing IVIG resistance, we re-analyzed our previous genome-wide association study (GWAS) data from 296 patients with KD, including 101 IVIG non-responders and 195 IVIG responders. Five nonsynonymous SNPs (nsSNPs) in five immune-related genes, including a previously reported SAMD9L nsSNP (rs10488532; p.Val266Ile), were associated with IVIG non-response (odds ratio [OR] = 1.89-3.46, P = 0.0109-0.0035). In a replication study of the four newly-identified nsSNPs, only one in the interleukin 16 (IL16) gene (rs11556218, p.Asn1147Lys) showed a trend of association with IVIG non-response (OR = 1.54, P = 0.0078). The same IL16 nsSNP was more significantly associated with IVIG non-response in combined analysis of all data (OR = 1.64, P = 1.25 × 10-4). Furthermore, risk allele combination of the IL16 CT and SAMD9L TT nsSNP genotypes exhibited a very strong effect size (OR = 9.19, P = 3.63 × 10-4). These results implicate IL16 as involved in the mechanism of IVIG resistance in KD.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31965063     DOI: 10.1038/s10038-020-0721-2

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  34 in total

1.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

2.  NFATc2 and NFATc3 regulate T(H)2 differentiation and modulate TCR-responsiveness of naïve T(H)cells.

Authors:  Jyothi Rengarajan; Betty Tang; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2001-12-10       Impact factor: 25.606

3.  Interleukin 16 expression in relation to disease activity in rheumatoid arthritis.

Authors:  S Blaschke; H Schulz; G Schwarz; V Blaschke; G A Müller; M Reuss-Borst
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

4.  Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice.

Authors:  A C Keates; I Castagliuolo; W W Cruickshank; B Qiu; K O Arseneau; W Brazer; C P Kelly
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

5.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

Review 6.  Sequelae of Kawasaki disease in adolescents and young adults.

Authors:  J C Burns; H Shike; J B Gordon; A Malhotra; M Schoenwetter; T Kawasaki
Journal:  J Am Coll Cardiol       Date:  1996-07       Impact factor: 24.094

7.  FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response.

Authors:  Robert Makowsky; Howard W Wiener; Travis S Ptacek; Miriam Silva; Aditi Shendre; Jeffrey C Edberg; Michael A Portman; Sadeep Shrestha
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

8.  Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response.

Authors:  Sadeep Shrestha; Howard Wiener; Aditi Shendre; Richard A Kaslow; Jianming Wu; Aaron Olson; Neil E Bowles; Hitendra Patel; Jeffrey C Edberg; Michael A Portman
Journal:  Circ Cardiovasc Genet       Date:  2012-05-07

Review 9.  The antiinflammatory activity of IgG: the intravenous IgG paradox.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2007-01-16       Impact factor: 14.307

Review 10.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

View more
  2 in total

Review 1.  Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.

Authors:  E Sapountzi; L Fidani; A Giannopoulos; A Galli-Tsinopoulou
Journal:  Pediatr Cardiol       Date:  2022-07-30       Impact factor: 1.838

2.  VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis.

Authors:  Shengyao Su; Qing Liu; Xueping Zhang; Xinmei Wen; Lin Lei; Faxiu Shen; Zhirong Fan; Jianying Duo; Yan Lu; Li Di; Min Wang; Hai Chen; Wenjia Zhu; Min Xu; Suobin Wang; Yuwei Da
Journal:  Ther Adv Neurol Disord       Date:  2021-01-27       Impact factor: 6.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.